2/9 Last week when we reported that Delta was only 2.3% I said: "This is probably more of a reflection of noisy data when trying estimate frequencies from a small number of cases", and followed that up with an expectation that we will see Delta 📈.
3/9 This week we are seeing the expected 📈 in Delta (B.1.617.2), but the caveat still remains that our estimates are noisy because of the low numbers of sequenced cases (a product of the low numbers of cases, which is a good problem to have 👍)
4/9 To improve our weekly estimates, we are now also including recently sequenced data from the CDC (typically samples tested by Quest Diagnostics).
5/9 Interestingly, the frequency of "Other variants" is going 📈 for the first time since our variant surveillance began in early 2021 (see 2x 👆). We are finding that this is being driven by lineage B.1.621.
6/9 While B.1.621 is not yet listed as a variant of concern/interest, but it has both the E484K and N501Y mutations found in Beta (B.1.351) and Gamma (P.1) that are known to decrease the efficacy of some vaccines. (source = outbreak.info)
7/9 B.1.621 represents <1% of the cases in the US and has not been detected in many places of the world.
**However**, B.1.621 represents ~15% of the sequenced cases in Colombia, and is recently trending 📈 in association with 📈 cases. (source = outbreak.info)
8/9 This is not to say that B.1.621 will become a concern here, I'm primarily highlighting what our surveillance system is intended to do: detect emerging lineages so that we can understand its epidemiology and inform public health. I'll provide updates as we learn more.
9/9 I'd like to thank the @CDC_AMD program, especially @dmaccannell, for not only providing financial support for sequencing, but also for 📈 their sequencing efforts to enhance our surveillance program in Connecticut. We greatly appreciate their commitment to open data sharing💪
• • •
Missing some Tweet in this thread? You can try to
force a refresh
It's based on a design led by @Scalene & @pathogenomenick originally for Zika virus that was adapted for SARS-CoV-2 ("ARTIC protocol") and used by labs around the world.
Our goal was for this to be plug n' play with current SARS-CoV-2 protocols. (2/8) nature.com/articles/nprot…
The primers were designed using PrimalScheme using a pre-outbreak A.1 clade reference genome (GenBank accession: MT903345).
The scheme comprises a total of 163 primer pairs with an amplicon length ranging between 1597 and 2497 bp (average length of 1977 bp). (3/8)
Using a logistic regression of the daily frequencies, we predict that as of today (July-14), BA.5 is probably 80-90% in Connecticut.
BA.4 is still 📈 as it outcompetes BA.2, but will probably start to 📉 in frequency soon after BA.2 is gone. (2/8)
We created a new dashboard to report variant sequencing data in Connecticut. You can still access it through our main website by clicking on the "Read the latest Connecticut report" link. (3/8)
Omicron BA.2.12.1 is still 📈 in Connecticut as it is across most of the US. Fitting the % of sequenced cases to a logistic growth curve, we estimate that BA.2.12.1:
1⃣ is ~80% frequency today (May019)
2⃣ surpassed 50% in early May
3⃣ may reach 95% in early/mid June
(2/13)
From the same logistic growth curve, we also estimate that BA.2.12.1 is:
➡️ ~24% more transmissible than background (mostly other BA.2 lineages)
➡️ doubling in proportion every ~12 days
(3/13)
Based on our TaqPath PCR data (S-gene detected), we estimate that:
➡️ BA.2 is >50% in Southern Connecticut
➡️ At this rate - BA.2 will be 95% by early April
➡️ BA.2 doubling rate = 7.8 days (BA.1 in December = 3-4 days)
➡️ BA.2 ~43% more transmissible than BA.1/.1
(2/7)
Over the past 4 weeks, all of the sequenced S-gene positive samples have been Omicron BA.2 and not Delta. So we trust the 👆 PCR results reflecting the rise in BA.2. (3/7)
Here are comparative results between 10 TaqPath S-gene detected samples tested by YNHH and with our validated VOC PCR assay. Most with our assay were actually SGTF, and looking at the YNHH results, the S-gene CTs for those were 5-7 higher than N/ORF. (5/16)
We are looking into these low level spike amplification samples that should be SGTF to see if this is a lab/TaqPath assay artifact or if there is something about these BA.1 sequences. So far doesn't seem to be sequence-related. Will report (6/16)
Our initial SGTF case definition – ORF/N <30 CT, S “not detected” - was conservative to not over-call BA.1.
We updated it yesterday to include S-gene 5 CTs higher than ORF/N, and compared the results. (7/16)